G
48.27
1.08 (2.29%)
| Penutupan Terdahulu | 47.19 |
| Buka | 48.09 |
| Jumlah Dagangan | 4,554,288 |
| Purata Dagangan (3B) | 5,296,903 |
| Modal Pasaran | 97,445,625,856 |
| Harga / Pendapatan (P/E TTM) | 13.71 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.39 |
| Harga / Jualan (P/S) | 2.32 |
| Harga / Buku (P/B) | 4.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2025 |
| Hasil Dividen (DY TTM) | 0.81% |
| Margin Keuntungan | 10.00% |
| Margin Operasi (TTM) | 30.79% |
| EPS Cair (TTM) | 2.07 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 55.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 134.99% |
| Nisbah Semasa (MRQ) | 0.870 |
| Aliran Tunai Operasi (OCF TTM) | 6.74 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 5.16 B |
| Pulangan Atas Aset (ROA TTM) | 6.55% |
| Pulangan Atas Ekuiti (ROE TTM) | 27.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - General (US) | Menaik | Menurun |
| Drug Manufacturers - General (Global) | Menaik | Menurun | |
| Stok | GSK plc | Bercampur | Bercampur |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.25 |
|
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - General |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.06% |
| % Dimiliki oleh Institusi | 18.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Jtc Employer Solutions Trustee Ltd | 30 Sep 2025 | 14,597,185 |
| Holocene Advisors, Lp | 30 Sep 2025 | 7,100,420 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Dec 2025 | CNBC | RFK Jr.'s vaccine panel defers vote on hepatitis B shot for babies until Friday |
| 23 Oct 2025 | Pengumuman | Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma |
| 01 Oct 2025 | Pengumuman | New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level |
| 19 Sep 2025 | CNBC | RFK Jr.'s vaccine panel postpones vote on whether to delay babies' first hepatitis B shot |
| Hasil Dividen (DY TTM) | 0.81% |
| Purata Hasil Dividen 3T | 3.09% |
| Nisbah Pembayaran | 80.20% |
| Jangkaan Pembayaran Dividen Seterusnya | Jan 2026 |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 15 Nov 2024 | 30 Oct 2024 | 09 Jan 2025 | 0.389052 Tunai |
| 16 Aug 2024 | 31 Jul 2024 | 10 Oct 2024 | 0.385671 Tunai |
| 16 May 2024 | 01 May 2024 | 11 Jul 2024 | 0.376185 Tunai |
| 22 Feb 2024 | 01 Feb 2024 | 11 Apr 2024 | 0.4060608 Tunai |
| 16 Nov 2023 | 01 Nov 2023 | 11 Jan 2024 | 0.3397772 Tunai |
| 17 Aug 2023 | 26 Jul 2023 | 12 Oct 2023 | 0.361256 Tunai |
| 18 May 2023 | 26 Apr 2023 | 13 Jul 2023 | 0.347508 Tunai |
| 23 Feb 2023 | 01 Feb 2023 | 13 Apr 2023 | 0.3403867 Tunai |
| 17 Nov 2022 | 02 Nov 2022 | 12 Jan 2023 | 0.3171217 Tunai |
| 18 Aug 2022 | 27 Jul 2022 | 06 Oct 2022 | 0.390832 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2025 | 0.389 | 1 | 0.81 |
| 2024 | 1.51 | 4 | 4.46 |
| 2023 | 1.37 | 4 | 3.69 |
| 2022 | 0.391 | 1 | 1.11 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |